A New Way to Identify Multiple Sclerosis Patients Likely to Experience More Rapid and Sustained EDSS Progression
Currently there are very limited ways to predict whether a patient disease will progress despite treatment. This can be especially important early after diagnosis, when initial treatment choices are being made.
This test is a panel of biomarkers specific to identifying patients who will progress towards higher EDSS scores despite treatment. The panel was studied in the BEtaferon® in Newly Emerging multiple sclerosis For Initial Treatment (BENEFIT) study. The gMS®Pro EDSS panel studied the time to confirmed EDSS progression. The analysis demonstrated gMS®Pro EDSS can significantly identify patients with higher risk for confirmed EDSS progression despite treatment within 5 years.
The gMS®Pro EDSS Test can help physicians identify which patients with Clinically Isolated Syndrome (CIS) or newly diagnosed Multiple Sclerosis (MS) will have a higher likelihood of progressing towards meaningful disabilities despite treatment. Physicians may want to consider more aggressive treatment for these patients.
In addition, the gMS®Pro EDSS test is targeted for use for diagnosed Multiple Sclerosis (MS) patients and potential MS patients who have had their first neurological event and will be starting therapeutic treatment for MS.
gMS® is a registered trademark of Glycominds. Patent US 7,572,592
|
